1. How risky is a second allogeneic stem cell transplantation?
- Author
-
Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Kröger, Nicolaus, Zeiser, Robert, Ciceri, Fabio, Schroeder, Thomas, Dreger, Peter, Passweg, Jakob, Schetelig, Johannes, Stelljes, Matthias, Blau, Igor Wolfgang, Franke, Georg-Nikolaus, Riesner, Katarina, Schoemans, Hélène, Moiseev, Ivan, and Peric, Zinaida
- Abstract
There is no consensus on second allogeneic stem cell transplantation (alloSCT) indications in patients with hematologic malignancies relapsing after a first alloSCT. In historic publications, a very high non-relapse mortality (NRM) has been described, arguing against performing a second alloSCT. We analysed the outcome of 3356 second alloSCTs performed 2011–21 following a hematologic malignancy relapse. Outcomes at two years after second alloSCT were: NRM 22%, relapse incidence 50%, overall survival 38%, and progression-free survival 28%. Key risk factors for increased NRM were: older age, low performance score, high disease-risk-index, early relapse after the first alloSCT, unrelated/haploidentical donor, and GVHD before second alloSCT. Any type of GVHD after first alloSCT was also important risk factor for acute GVHD and chronic GVHD after second alloSCT. There was a preferential use of a different donor (80%) at second alloSCT from first alloSCT. However, in multivariate analysis, the use of the same alloSCT donor for second alloSCT vs. a different donor was not associated with any of the survival or GVHD endpoints. We show considerably improved outcome as compared to historic reports. These current data support a wider use of second alloSCT and provide risk factors for NRM that need to be considered.
- Published
- 2024
- Full Text
- View/download PDF